Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
Cullinan Therapeutics, Inc. CGEM

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 14, 2026 8-K 13 signals fired
Core
Combination Therapy Mentioned Clinical Trial Result Lead Asset Progress Indication Expansion Secondary Endpoint Mentioned
Other
Interim Data Positive Kol Endorsement Safety Differentiated Publication Positive Patient Retention High Fda Aligned Checkpoint Inhibitor Program Expanded Access Program Active
Aug 12, 2026 8-K 18 signals fired · top 15
Other
Interim Data Positive Board Committee Member Listing Fda Aligned Patient Retention High Safety Differentiated Publication Positive Kol Endorsement Enrollment Ahead Of Schedule Ip Protection Methods Disclosed
Core
Indication Expansion Combination Therapy Mentioned Clinical Trial Result Lead Asset Progress Secondary Endpoint Mentioned Clinical Hold
Jun 16, 2026 8-K 0 signals fired
No signals above threshold for this filing.
Jun 10, 2026 8-K 20 signals fired · top 15
Core
Clinical Trial Result Lead Asset Progress Indication Expansion Clinical Hold Secondary Endpoint Mentioned
Other
Interim Data Positive Safety Differentiated Patient Retention High Fda Aligned Expanded Access Program Active Enrollment Ahead Of Schedule Kol Endorsement Publication Positive Fast Track Granted
Biotech Risk
Clinical Hold Active
Jun 8, 2026 8-K 16 signals fired · top 15
Core
Clinical Trial Result Secondary Endpoint Mentioned Lead Asset Progress Clinical Hold Combination Therapy Mentioned
Other
Interim Data Positive Patient Retention High Publication Positive Expanded Access Program Active Fda Aligned Kol Endorsement Enrollment Ahead Of Schedule Safety Differentiated
Biotech Risk
Crl Received Clinical Hold Active
May 18, 2026 8-K 15 signals fired
Core
Clinical Trial Result Patient Enrollment Velocity Lead Asset Progress Secondary Endpoint Mentioned Clinical Hold
Other
Patient Retention High Fda Aligned Interim Data Positive Safety Differentiated Expanded Access Program Active Publication Positive Protocol Amended Fast Track Designation Received Enrollment Ahead Of Schedule Fast Track Granted
May 7, 2026 10-Q 19 signals fired · top 15
Other
Financing Activities Cash Flow Disclosure Operating Lease Rent Expense Disclosed Shares Outstanding Disclosure Cash Flow Statement Investing Activities Administrative Efficiency Codm Segment Reporting Disclosure Expanded Access Program Active Fast Track Designation Received Other Income Expense Disclosure Enrollment Ahead Of Schedule Interim Data Positive
Core
Clinical Trial Result Lead Asset Progress Indication Expansion Clinical Hold
May 7, 2026 8-K 17 signals fired · top 15
Other
Net Loss Reported Priority Review Or Pdufa Disclosed Kol Endorsement Safety Differentiated Car T Cell Therapy Interim Data Positive Enrollment Ahead Of Schedule Protocol Amended
Core
Near Term Regulatory Decision Clinical Trial Result Indication Expansion Clinical Hold Lead Asset Progress
Biotech v3
Ind Submission Planned
Biotech Risk
Clinical Hold Active